NEW YORK, Sept. 17, 2013 /PRNewswire/ -- Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of OvaScience, Inc. ("OvaScience" or the "Company") (NASDAQ: OVAS), concerning whether the board has breached its fiduciary duties to shareholders.

(Logo: http://photos.prnewswire.com/prnh/20120215/MM54604LOGO )

On September 10, 2013, the Company disclosed that it was suspending enrollment in connection with its proprietary technology, Augment, in the U.S. after receiving an "untitled" letter from the FDA "questioning the status of Augment… and advising the Company to file an Investigational New Drug (IND) application."     

Our investigation concerns whether the Company board of directors has breached its fiduciary duties to shareholders, grossly mismanaged the Company, and/or committed abuses of control in connection with the foregoing.

If you own OvaScience shares and wish to discuss this matter with us, or have any questions concerning your rights and interests with regard to this matter, please contact:

Robert I. Harwood, Esq.Matthew M. Houston, Esq.Benjamin I. Sachs-Michaels, Esq.Harwood Feffer LLP488 Madison AvenueNew York, New York 10022Phone Numbers: (877) 935-7400                         (212)935-7400Email:  bsachsmichaels@hfesq.comWebsite:   http://www.hfesq.com

Harwood Feffer has been representing individual and institutional investors for many years, serving as lead counsel in numerous cases in federal and state courts. Please visit the Harwood Feffer LLP website (http://www.hfesq.com) for more information about the firm.

Attorney Advertising. © 2013 Harwood Feffer LLP. The law firm responsible for this advertisement is Harwood Feffer LLP (www.hfesq.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter.

SOURCE Harwood Feffer LLP

RELATED LINKShttp://www.hfesq.com